Jpmorgan Chase & CO Bio N Tech Se Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Bio N Tech Se stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,772 shares of BNTX stock, worth $181,824. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,772
Previous 10,090
82.44%
Holding current value
$181,824
Previous $1.15 Million
85.99%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding BNTX
# of Institutions
321Shares Held
40.9MCall Options Held
1.38MPut Options Held
1.52M-
Baillie Gifford & CO8.04MShares$825 Million0.67% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.23MShares$434 Million1.88% of portfolio
-
Primecap Management CO Pasadena, CA4MShares$411 Million0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.6MShares$369 Million0.24% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$194 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $24.9B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...